Pantheris
Avinger Announces FDA Clearance of Pantheris for the Treatment of In-Stent Restenosis
"We are excited to receive FDA clearance for the ISR indication, which expands our addressable market for Pantheris to include a high-incidence disease state for which there are few available indicated treatment options," commented Jeff Soinski, Avinger's President and CEO.